Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

@article{Shimamura2006NonsmallcellLC,
  title={Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.},
  author={Takeshi Shimamura and Hongbin Ji and Yuko Minami and Roman K. Thomas and April M. Lowell and Kinjal Shah and H. -G. Greulich and Karen A Glatt and Matthew Meyerson and Geoffrey I. Shapiro and Kwok-kin Wong},
  journal={Cancer research},
  year={2006},
  volume={66 13},
  pages={6487-91}
}
Mutation-specific cancer therapy has shown promising clinical efficacy. In non-small-cell lung cancer (NSCLC), the presence of mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase correlates with clinical response to small-molecule tyrosine kinase inhibitors. Here, we show that cells harboring the G776insV_G/C mutation in the related… CONTINUE READING